News

The ACRO Residents Committee is hosting a webinar on Wednesday, December 9, from 5-6 PM EST, on the Path to FDA Approval for a Drug with Radiation. Featured Speaker: Dr. Amanda Walker About this Webinar: Dr. Amanda Walker is a radiation oncologist at the Johns Hopkins Kimmel Cancer Center and treats patients in the Greater … Continue reading “ACRO Webinar: The Path to FDA Approval for a Drug with Radiation – Real and Perceived Barriers and How to Overcome Them”

We are increasingly optimistic that Congress will act to mitigate the large cut some specialties face in 2021 due to E/M code changes in the physician fee schedule. We’ve grown more bullish over the past month as spiking Covid-19 cases threaten physician practice incomes and specialty groups have developed a more cohesive lobbying strategy for … Continue reading “Providers: Outlook Brightens for Temporary E/M Code Reimbursement Patch”

While we think a stimulus package is still likely in Q1 2021, we think the markets are underappreciating the real possibility of no additional broad material stimulus forthcoming from Congress beyond some direct help for the healthcare sector. Now, if the Democrats win the two Senate seats in Georgia, this all becomes somewhat moot, as … Continue reading “Phase 4 Stimulus: Go Small or Go Home?”

PFE’s Big Vaccine Reveal The 90+% effectiveness rate demonstrated via 94 clinical trial participants infected with the virus exceeds expectations and FDA’s minimum 50% effectiveness threshold. PFE intends to apply for FDA emergency authorization later this month. The announcement timing, a mere two days after the presidential election was called for VP Biden, is questionable. … Continue reading “DC Dose – Health Care Weekly”

November 9, 2020 | HEALTH CARE The U.S. Supreme Court will hear oral arguments at 10 AM ET tomorrow (11/10) in the consolidated case of CA v. TX. A decision is expected in the spring of 2021, likely in June. Due to the pandemic, the Court will hear arguments via an audio call, which will … Continue reading “CA v. TX: Updated Odds and Tomorrow’s Oral Arguments”

November 6, 2020 | HEALTH CARE • With a likely Biden White House and GOP Senate, Democrats’ big plans to expand health care coverage are scuttled, leaving Biden to pursue more incremental ACA policy changes via administrative and regulatory authorities. We detail the likely changes in this note. • Democrats’ plans to legislatively preempt the … Continue reading “Democrats’ Big Health Agenda Scuttled; What’s Realistic for ACA, Covid Stimulus”

November 6, 2020 | MACRO • If elected, Joe Biden will be the first president in more than thirty years to take office without majority control of both Houses. What’s more, Congress is more polarized than in the past, making it likely that Biden’s legislative agenda will be limited at best. There will be no … Continue reading “Georgia Runoff, Stimulus, Next Year’s Legislative Agenda”

Joe Lieber, 202-756-7704 jlieber@washingtonanalysis.com Ryan Schoen, 202-756-7709 rschoen@washingtonanalysis.com Yesterday, we hosted a conference call with University of Iowa law professor Derek Muller to discuss the potential legal paths to victory in the election for President Trump and Joe Biden. Trump’s campaign has filed suit in a number of states, though we doubt he is successful … Continue reading “Call Takeaways: Election Law Expert on a Contested Election”

THE COWEN INSIGHT The healthcare sector would arguably be best-positioned if Joe Biden goes on to win the White House, and the Senate stays Republican, which appears to be the current trajectory – though by no means certain (see commentary from our colleague Chris Krueger). Pharma: For the branded biopharma sector, such an outcome would … Continue reading “Divided Gov’t Likely Best for Outcome for Healthcare Industry – Cowen and Company”

Addressing prescription drug pricing has been a top tier populist issue for President Trump since his 2016 candidacy. His press for a demonstration to tie Medicare drug prices to what other countries pay has defined much of the health care agenda for the second half of his term. Trump doubled down on this concept with … Continue reading “Drug Pricing: Part B Reforms Likely Back Burnered Under Biden”